Lastly, we want to emphasize that the observed dichotomy in expression pattern within ATRX aberrant neuroblastoma suggests the potential need for two distinct treatment regimens, since the ATRXΔ2–10 and the ATRXΔ2–13&-/- tumor cells are molecularly very distinct and are therefore likely to respond differently to the same treatment regimen. This evidence concerns the gene ATRX and neoplasm.